Noteworthy Tuesday Option Activity: ALB, PEN, LHX

Penumbra Inc (PEN) saw 2,210 options contracts trade (≈221,000 underlying shares), equal to roughly 47.1% of PEN's one‑month average daily share volume (469,440), led by 610 contracts in the $320 Jan 16, 2026 call (≈61,000 shares). L3Harris Technologies (LHX) recorded 5,505 contracts (≈550,500 underlying shares), about 46.2% of its one‑month average daily volume (~1.2M), with 468 contracts in the $350 Jan 16, 2026 call (≈46,800 shares). The prints indicate concentrated call activity and notable options positioning in both names, which may drive near‑term equity flow and volatility specific to PEN and LHX.

Analysis

Market structure: The concentrated call flow (PEN ~47% of ADV; LHX ~46% of ADV) is large enough to create measurable short-term buy-side pressure via delta-hedging and dealer hedging flows, particularly into the Jan 16, 2026 $320 (PEN) and $350 (LHX) strikes. Market-makers will buy underlying stock to hedge long-dated calls, tightening liquidity and potentially compressing skew/raising near-term implied volatility; ETFs and sector futures may see small inflows if flows broaden to peers.

Risk assessment: Tail risks differ by ticker — PEN (medical devices) carries regulatory/clinical binary risk where a negative FDA/clinical event could wipe out option premium; LHX (defense) has geopolitics/contract-award risk that can gap on budget headlines. Timeframes: expect immediate (days) delta-hedge-driven moves of 1–5%, short-term (weeks–months) IV re-pricing, and long-term (quarters) fundamentals to dominate. Hidden dependency: crowded long-call positioning can produce violent reversals if liquidity providers unwind; catalyst windows include earnings, FDA decisions, and defense budget votes within next 3–12 months.

Trade implications: Prefer defined-risk option exposure rather than outright equities. For directional bullish exposure buy vertical call spreads in Jan 2026 to capture upside from flow-driven re-rating while capping premium; consider selling short-dated premium if IV front-month >1.3x realized volatility to monetize anticipated IV mean reversion. Size positions small (0.5–2% portfolio each) and use 50% stop-loss on premium.

Contrarian angles: The market may be mistaking flow-driven momentum for conviction; heavy call volume can be hedging of existing long stock positions or synthetic activity rather than genuine new-money bullishness. Historically, large one-sided option flow preceded sharp mean-reversions in names with binary risks (notably biotech); if IV spikes >30% without fundamental support, consider fading into strength and shorting volatility ahead of option expiry.

Key Decisions for Investors

• PEN: Establish a defined‑risk bullish vertical — buy Jan 16 2026 $320/$420 call spread (or nearest liquid wings) sizing at 0.5–1.0% of portfolio. Target 100%+ return if PEN tops mid‑spread by expiry; cut premium at 50% loss or exit 30–60 days before any FDA/clinical event.
• LHX: Buy Jan 16 2026 $350/$430 call spread sized 1.0–2.0% of portfolio to play flow-driven upside while capping downside. Take profits at 50–100% and trim if LHX rallies >8% intra-trade or if defense budget headlines are negative.
• Volatility sell trigger: If 30‑day IV exceeds realized HV30 by >30% (IV30 >1.3*HV30), sell 30–60 day calls (covered if long stock) or short-call calendars equal to 0.5% notional per name; unwind on IV contraction >25% or after 45 days.